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Abstract 
Diabetes mellitus is one the most frequent co-morbid conditions in patients with chronic kidney disease (CKD), frequently leading to chronic 
kidney failure. Progression of CKD accelerates several metabolic disorders, predominantly those related to abnormalities of carbohydrate 
metabolism. Patients with CKD are usually characterised by an insulin resistance additionally aggravated by several co-morbid condi-
tions (for example chronic low-grade inflammation). Treatment with anti-diabetic medications in patients with CKD remains a challenge 
because, along with the disease progression, the dosing of several drugs needs to be adjusted to the reduced kidney function (especially 
those that are excreted intact with urine or as active metabolites). Progression of CKD also increases the risk of hypoglycaemia in patients 
treated with anti-diabetic drugs, and other adverse drug reactions may occur more frequently. Usefulness of the new generation drugs 
has not yet been verified in patients with advanced kidney disease (although some of them act through kidney-related mechanisms). The 
current position statement of the Polish Society of Nephrology Working Group provides practical recommendations for the diagnosis and 
treatment of type 2 diabetes mellitus in patients with CKD and reduced kidney function. (endokrynol Pol 2020; 71 (1): 3–14)
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Introduction
It is estimated that 8 to 9% of the world population 
suffers from diabetes mellitus (in up to 90% of them 
it is classified as diabetes type 2 — T2D) [1]. Epide-
miological analyses suggest that in 15–20% of diabetic 
patients the glomerular filtration rate (GFR) is lower 
than 60 mL/min/1.73 m2 [2–4]. 
Chronic kidney disease (classified according to KDI-
GO into stages 1–5), in particular — stages 3a–5, may 
significantly worsen metabolic regulations in diabetic 
patients and influence the efficacy and safety of several 
glucose-lowering drugs. The aim of this Position State-
ment paper is to analyse and discuss the differences in 
the clinical course, diagnosis, and treatment of T2D in 
patients with CKD. Our statement is largely limited 
to patients with GFR lower than 60 mL/min/1.73 m2 
(above this GFR most of the diagnostic and therapeutic 
approaches do not differ from those applied in patients 
with normal kidney function). The Working Group 
aimed to develop the opinions (summarised in Tab. 1) 
that might be helpful for nephrologists and other 
practitioners in the treatment of T2D in the setting of 
co-existing CKD of any aetiology. 
Statement 1 
Chronic kidney disease causes a potentially “diabetogenic” 
milieu because it leads per se to carbohydrate metabolism 
disturbances and enhances insulin resistance. Several drugs 
used in the treatment of kidney diseases impair glucose 
metabolism. Conversely, because renal tissue contributes to 
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other drugs may adversely influence the carbohydrate 
metabolism but are also prone to interactions with 
other therapeutic agents (including glucose-lowering 
ones) [9]. 
Statement 2 
Concomitant CKD does not influence the diagnostic criteria 
of T2D commonly accepted in the general population. HbA1c 
is less precise and accurate in monitoring diabetes control, 
but, since no other tool has been developed and validated, it 
should also be used in diabetic patients with CKD for this pur-
pose. Along with CKD progression, in T2D patients higher 
values of HbA1c (i.e. 7–8%) should be accepted as targets of 
metabolic control. 
Commentary to Statement 2
The diagnostic criteria of T2D in patients with CKD 
are the same as for the general population (regardless 
of the CKD stage); the same applies for the criteria of 
metabolic control in T2D. The target HbA1c in CKD 
patients (depending of the disease stage) remains the 
subject of controversies. Renal anaemia, iron deficiency, 
haemolysis, and shortened life-span of red blood cells, 
but — on the other hand — increase production of 
new red blood cells upon stimulation with the eryth-
ropoiesis stimulating agents, comprise the factors that 
may have an impact on the interpretation of HbA1c as 
a marker of long-term metabolic control in diabetes 
with concomitant CKD. It is generally accepted that 
in CKD patients, the level of HbA1c tends to underes-
timate the true exposure to hyperglycaemia. Despite 
these controversies and the fact that in advanced 
CKD there is no clear relationship between HbA1c and 
long-term patient prognosis, HbA1c and glycaemia 
remain the only tools for the assessment of metabolic 
control in diabetic patients with concomitant CKD. 
Other proposed markers used for control monitoring 
insulin catabolism, decreasing kidney function resulting in 
impaired insulin clearance may lead to the decreased demand 
for exogenous insulin.
Commentary to Statement 1
Chronic kidney disease influences the carbohydrate 
metabolism, which may result in so-called “pseudodia-
betes” in non-diabetic patients with CKD, and worsen-
ing of metabolic control in those with established T2D. 
The most important factors accompanying CKD that 
may influence carbohydrate metabolism include [5–7]:
 — impaired insulin secretion (caused, among others, 
by secondary hyperparathyroidism);
 — increasing insulin resistance (which becomes ap-
parent when GFR falls below 50 mL/min/1.73 m2); 
 — impaired renal and hepatic catabolism of insulin, 
with impaired clearance of this hormone; 
 — reduced renal gluconeogenesis. 
The above-mentioned disturbances are even more 
advanced in patients with end-stage renal diseases 
(ESRD) treated with dialysis (both peritoneal dialysis 
and haemodialysis) and following kidney transplanta-
tion. In the latter group of patients, disturbances typical 
for CKD without diabetes are additionally complicated 
by de novo development of diabetes (post-transplanta-
tion diabetes mellitus — PTDM) [8]. 
Severe proteinuria is frequently present in patients 
with chronic kidney diseases; resulting in hypopro-
teinaemia and hypoalbuminaemia. The most obvious 
consequence of hypoalbuminaemia is increased free 
fraction of protein-bound glucose-lowering drugs. This 
may unpredictably increase their pharmacological ac-
tivity and lead to unexpected hypoglycaemia. It should 
be kept in mind that several primary and secondary 
proteinuric kidney diseases are treated with ‘diabe-
togenic’ drugs, such as steroids (used in high doses 
and in prolonged courses) and calcineurin inhibitors 
(cyclosporine, and especially tacrolimus). These and 
Table 1. Diagnosis and treatment of type 2 diabetes (T2D) in patients with chronic kidney disease (CKD):  summary of the 
Working Group statements 
1.	 CKD	is	potentially	“diabetogenic”	state	since	it	leads	per	se	to	the	carbohydrate	metabolism	disturbances	and	enhances	insulin	resistance.	
Several	drugs	used	in	the	treatment	of	kidney	diseases	impair	glucose	tolerance.	In	opposite,	since	renal	tissue	contributes	to	insulin	
catabolism,	decreasing	kidney	function	resulting	in	impaired	insulin	clearance	may	lead	to	the	decreased	demand	for	exogenous	insulin.		
2.	 Concomitant	CKD	does	not	influence	the	diagnostic	criteria	of	T2D	commonly	accepted	in	the	general	population.	HbA1c	is	less	precise	and	
accurate	in	monitoring	of	diabetes	control,	but	—	since	no	other	tool	has	been	developed	and	validated	–	it	should	also	be	used	in	diabetic	
patients	with	CKD.	Along	with	CKD	progression	higher	values	of	HbA1c	(i.e.	7–8%)	should	be	accepted	acceptable	for	optimal	metabolic	control	
in	patients	with	T2D.	
3.	 The	glomerular	filtration	rate	(GFR)	is	one	of	the	key	factors	in	choosing	the	type	of	glucose-lowering	agent.	The	risk	of	adverse	events	
of	glucose-lowering	drugs	increases	along	with	decreasing	GFR.	In	the	treatment	of	T2D	with	concomitant	CKD	drugs	with	proven	
cardiovascular	benefits	(i.e.:	metformin,	SGLT2	inhibitors,	and	GLP1	receptor	agonists)	should	be	preferred	unless	not	contraindicated	in	a	
certain	GFR	range.	
4.	 Demand	for	exogenous	insulin	decreases	with	decreasing	GFR,	although	the	relationship	between	GFR	and	insulin	doses	is	non-linear,	and	
several	other	factors	influence	the	need	for	exogenous	insulin.	
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in diabetic patients (such as fructosamine or glycated 
albumin) are also influenced by CKD-dependent fac-
tors, and — in addition — none of them was validated 
in CKD patients [10].
It is generally assumed that the “standard” targets 
of metabolic control are less achievable with decreas-
ing values of GFR. Advanced CKD is associated with 
higher risk of hypoglycaemia, and the consequences 
of hypoglycaemia may be more pronounced in this 
patient group. In addition, several advanced comor-
bidities (especially cardiovascular disease) impair the 
overall prognosis of CKD patients, and therefore strict 
metabolic control of glycaemia may not be beneficial 
and prolong survival. Thus, higher values of HbA1c 
are generally acceptable, especially in CKD stages 
3b–5. European experts from the European Renal Best 
Practice (ERBP) group suggest 8.5 as a target for HbA1c 
in patients with GFR lower than 45 mL/min/1.73 m2 
[11]. Most other guidelines aimed at an HbA1c level 
of 7% or less to prevent microvascular complications 
of diabetes also in patients with concomitant CKD, 
but achievement of these values should not be at-
tempted in patients with high risk of hypoglycaemia. 
Experts agreed that HbA1c exceeding 7% should be 
accepted in patients with multiple and advanced 
comorbidities, short expected survival, and high risk 
of hypoglycaemia [12–14]. Studies demonstrated 
that an association between HbA1c and outcome in 
CKD is “J”-shaped — prognosis worsens with HbA1c 
below 6.5% and above 8%. A similar relationship was 
also observed in dialysis patients [15]. Higher values 
of HbA1c (i.e. between 7% and 8%) as a criterion of 
long-term metabolic control were based on stud-
ies comprising high-risk patient groups (ACCORD, 
ADVANCE, VADT) and applied also to patients with 
CKD stages 3–5 [13]. 
Statement 3 
The glomerular filtration rate (GFR) is one of the key 
factors in choosing a glucose-lowering agent. The risk 
of adverse events of glucose-lowering drugs is higher in 
patients with lower GFR. In the treatment of T2D with 
concomitant CKD drugs with proven cardiovascular benefits 
(i.e. metformin, SGLT2 inhibitor, and GLP1 receptor agonist) 
should be preferred unless not contraindicated in a certain 
GFR range. 
Statement 4 
Demand for exogenous insulin decreases in patients with 
decreased GFR, although the relationship between GFR and 
insulin doses is not linear, and several other factors influence 
the need for exogenous insulin. 
Commentaries to Statements 3 and 4
Whereas the diagnostic criteria of T2D in CKD are 
universal and shared with those accepted in the gen-
eral population, the choice of hypoglycaemic drug is 
largely influenced by the GFR value. Modification of 
pharmacological therapy in T2D with concomitant 
CKD (especially stages 3–5) should take into account 
the following aspects [16, 17]:
 — different pharmacokinetic and pharmacodynamic 
characteristics of the drug (depending on the con-
tribution of the kidneys to the drug metabolism 
and/or elimination, as well as the presence and 
renal clearance of active metabolites); all mentioned 
circumstances mandate the adjustment of drug dose 
to the GFR;
 — potential toxic effects of the drug to the organs and 
systems other than the kidneys in case of renal 
elimination of the drug or its active metabolites (due 
to their accumulation in CKD stages 3–5); severe 
adverse effects may include the risk of unpredictable 
and profound hypoglycaemia;
 — difficulties in predicting the drug absorption in the 
case of uremic gastroparesis (frequently present 
in diabetic patients) and GI mucous oedema (in 
patients with severe fluid retention and/or severe 
proteinuria);
 — the impact of other drugs commonly used for the 
treatment of CKD and concomitant diseases on 
glucose-lowering drug absorption. These include: 
proton pump inhibitors (overused in the general 
population and CKD patients), phosphate bind-
ers, oral iron supplementation, and drugs used as 
alkalinising agents;
 — the impact of hypoproteinaemia caused by se-
vere proteinuria on free (unbound) fraction of 
glucose-lowering drugs;
 — insulin resistance, increasing in patients with de-
creased GFR. 
The question remains whether the targets of meta-
bolic control that are expected to be achieved using 
a particular drug in a patient with certain stage of CKD 
(i.e. glycaemia or HbA1c) would translate into clini-
cally important end points, such as decreased risk of 
cardio-vascular or cerebrovascular events, or prolonged 
survival. Before reviewing the use of glucose-lowering 
drugs in CKD we would like to emphasise that along 
with progressive loss of GFR the expected benefits from 
using a particular drug and better metabolic control are 
reduced. CKD is one of the strongest predictors of ad-
verse outcome in patients with T2D. Intensive hypogly-
caemic treatment and/or achieving targets of glycaemic 
control has little impact on patients’ outcome when GFR 
is reduced below 60 mL/min/1.73 m2. The same applies 
to other interventions, such as lipid-lowering treatment. 
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Non-pharmacological treatment of T2D 
with concomitant CKD
The diet prescribed to T2D patients is generally benefi-
cial also in patients with chronic kidney disease (i.e. it 
may slow down the CKD progression). Unfortunately, 
in CKD stages 3 to 5, establishing a well-balanced 
and valuable diet becomes more difficult because 
new restrictions must be introduced along with GFR 
loss. The most important one is the need to limit potas-
sium intake, with a reduction of vegetable content in 
the diet. One of the dietary restrictions of paramount 
importance for both nephroprotection and reduction 
of organ damage in CKD is reduced phosphate intake. 
This is a special challenge in patients with CKD because 
a low-phosphate diet is usually low in protein as well. 
Advanced CKD is a catabolic and “inflammatory” 
state — restricting protein intake may further impair 
nutritional status and eventually lead to sarcopaenia, 
cachexia, and MIA syndrome (malnutrition, inflam-
mation, atherosclerosis). Therefore, it is recommended 
that the daily protein intake should not be lower than 
0.8 g/kg body weight (unless not supplemented with 
amino acid ketoanalogues). 
Using glucose-lowering drugs in CKD 
Metformin
Metformin is entirely excreted by the kidneys. Metfor-
min is not nephrotoxic per se; however, kidney failure 
may promote extra-renal toxicities of this drug. No 
controlled trials have been completed to prospectively 
demonstrate the renal (nephroprotective) benefits of 
metformin. Retrospective, observational studies sug-
gest that patients treated with metformin experience 
slower progression of CKD (in terms of lower rate of 
the GFR loss and progression to ESRD) as compared 
to those treated with sulphonylurea agents. These 
data indirectly suggest nephroprotective properties of 
metformin. The most important factor that limits the 
use of metformin in patients with reduced GFR is a risk 
of severe lactic acidosis. The risk of this life-threatening 
complication prompted all groups of experts to suggest 
adjustment of drug dosing to GFR and withdrawal of 
metformin in advanced stages of CKD [18–20]. 
Large observational studies focusing on the inci-
dence of lactic acidosis in metformin-treated patients 
suggest that the risk of this complication is very low and 
largely comparable to the risk observed in patients who 
are treated with the other glucose-lowering agents. In 
one of the analyses the frequency of lactic acidosis was 
3.3 per 100,000 metformin users and 4.8 per 100,000 
patients not using this drug. In the same study hypogly-
caemia was found in 60 out of 100,000 patients treated 
with metformin and 110 per 100,000 who were using 
other drugs. Frequency of severe hypoglycaemia was 
20 times higher in patients who were treated with other 
drugs as compared to metformin users [18]. Overall, it 
seems that between 25% and 33% of patients with T2D 
and CKD stage 3 are treated with metformin (frequently 
without proper dose adjustment) [21]. Some experts 
argue that metformin can be used in a dose of 500 mg 
once daily also in T2D patients with GFR 15–30 mL/min 
(with temporary withholding or withdrawal, when GFR 
is lower than 15 mL/min) [22]. In the NHANES study 
as many as 40% of patients with T2D and CKD3 were 
treated with metformin. The incidence of lactic acidosis 
increased along with the GFR reduction, but it was 
usually without important clinical consequences [23]. 
In patients with lactic acidosis apparently associated 
with the use of metformin, the blood concentration of 
the drug was either normal or elevated.  There was also 
no significant correlation between metformin blood 
concentration and the severity of lactic acidosis [18]. 
When prescribing metformin, it is advisable to take into 
account a few additional “safety rules”: 
 — cimetidine inhibits tubular excretion of metformin 
– its concomitant use may promote retention of 
metformin, even when GFR is preserved;
 — temporary drug withdrawal may be considered 
(although is not mandatory in all patients) in clini-
cal settings that expose patients to the risk of CKD 
worsening (for example, when intra-arterial contrast 
media are injected);
 — patients treated with metformin should monitor 
their kidney function and consult with their doctors 
regarding further treatment in such situations as: 
fever, vomiting, diarrhoea, dehydration, any noticed 
decrease in urine volume (also due to “post-renal” 
causes);
 — special attention should be paid to patients using 
metformin, CKD patients, and those with concomi-
tant liver failure (that impairs lactate metabolism) or 
clinical situations that increase the risk of hypoxia 
(i.e. worsening of chronic obstructive pulmonary 
disease, congestive heart failure, etc.). 
Recently, changes were made to the summaries 
of product characteristics of some metformin prepa-
rations. In some of them it has been stated that the 
drug can be used when GFR decreases to the range 
between 30 and 60 mL/min; if GFR is between 30 and 
44 mL/min, the initial dose should not exceed 50% of 
the maximum dose (i.e. 1000 mg/d), whereas in the GFR 
range of 45–59 mL/min it may be used in a full dose of 
2000 mg/d (being still contraindicated when GFR falls 
below 30 mL/min). This means that metformin may not 
only be continued in a reduced dose, but also initiated in 
moderate stages of CKD. We emphasise this fact because 
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such changes in the product characteristics follow the 
data obtained from clinical observations and meet the 
needs of practitioners. 
Recommendations concerning metformin dosing 
according to expert groups in relation to GFR are shown 
in Table 2. 
Pioglitazone
Taking into account its pharmacokinetic (PK) properties, 
pioglitazone seems to be an “ideal” drug for patients 
with all stages of CKD (including advanced renal fail-
ure) — it is not excreted by the kidneys and does not 
accumulate in patients with advanced CKD. In addi-
tion, the PROactive trial demonstrated that treatment 
with pioglitazone reduced the risk of cardio-vascular 
events, and the beneficial effects were independent 
from the renal function [26]. Nevertheless, there are 
several important limitations to the use of this drug in 
patients with CKD, despite the above-mentioned PK 
properties [17, 20, 25]:
 — the drug promotes water and sodium retention and 
oedema formation – these are common problems in 
CKD patients;
 — the drug should not be used in patients with heart 
failure (up to 40% of patients with T2D and ad-
vanced CKD suffer from heart failure of varying 
severity);
 — the albumin-bound fraction of a drug is close to 98%, 
which makes the pharmacokinetic and pharmaco-
dynamic properties of the drug largely unpredict-
able in CKD patients with severe proteinuria;
 — the drug is metabolised by the cytochrome P450, 
which contributes to the metabolism of several other 
drugs used in the treatment of patients with chronic 
kidney diseases (including calcineurin inhibitors); in 
addition, several drugs can inhibit or activate cyto-
chrome P450, modifying the drug inactivation rate. 
These data indicate that in the case of pioglitazone 
(more than in the case of other glucose lowering 
agents) potential drug interactions may be expected.
Sulphonylurea derivates (SU) 
Each of the drugs in this group has slightly different 
characteristics in relations to kidney function. All have 
strong affinity to plasma proteins, are predominantly 
eliminated by the liver, and to a small degree are ex-
creted by kidneys (although kidneys may significantly 
contribute to the clearance of their metabolites, they 
usually do not exert glucose-lowering properties). 
Other drugs with high affinity to protein (among oth-
ers, b-receptor antagonists and warfarin) may lead to 
an increase in free SU blood concentration. Glipizide 
is metabolised exclusively to non-active metabolites 
by the liver, and less than 10% of the drug is excreted 
with urine. PK of glipizide is virtually unchanged in 
patients with CKD, and therefore glipizide is consid-
ered a very ‘convenient’ drug for these patients. The 
same applies to gliquidone. Gliclazide is also metabo-
lised to inactive by-products, and its dosing should 
not be adjusted to the GFR value (although the 
treatment should always be started from low doses, 
then up-titrated). Extended release formulations of 
gliclazide are generally considered safe in terms of 
risk of hypoglycaemia in patients with reduced GFR. 
It is generally thought that hypoglycaemic episodes 
following SU may be more pronounced in patients 
Table 2. Dosing recommendations of metformin adjusted to the kidney function (based on [18, 19]) 
eGFR  
[mL/min/1.73 m2] Dosage 
Maximum daily dose 
[mg]
≥	90	(G1) Dose	modification	unnecessary
Renal	function	assessment	annually
3000
60–89	(G2)
45–59	(G3a)
Treatment	can	be	continued
Renal	function	assessment	every	3–6	months
Should	not	be	used	in	patients	with	unstable	renal	function	or	when	significant	renal	function	
worsening	can	be	expected*
2000
30–44	(G3b)
Can	be	used	with	caution
The	treatment	should	not	be	started
The	dose	should	not	exceed	50%	of	the	maximum	registered	dose
Renal	function	assessment	at	least	every	3	months
Should	not	be	used	in	patients	with	unstable	renal	function	or	when	significant	renal	function	
worsening	can	be	expected*
1000
<	30	(G4–G5) Contraindicated –
eGFR	—	estimated	glomerular	filtration	rate;	*using	metformin	in	patients	with	CKD	stage	3	is	not	in	accordance	with	the	summary	of product	characteristics	(SPC):	
SPCs	of	available	preparations	state	that	they	are	contraindicated	if	creatinine	clearance	is	lower	than	60	mL/min
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with reduced GFR; this is especially true in the case of 
glimepiride, which is metabolised to active products 
that may accumulate in the setting of CKD. For this 
reason, the drug should not be used in patients with 
CKD stage 5, and the dose of 1 mg should not be ex-
ceeded in CKD stages 3–4 [16, 17, 20, 27, 28]. 
Acarbose
Less than 2% of acarbose dose is absorbed from the 
GI lumen; however, some metabolites possessing glu-
cose-lowering activity may achieve clinically important 
concentrations in the blood in patients with advanced 
CKD. Although the excess rate of side effects in CKD 
was not confirmed, the drug is contraindicated when 
GFR falls below 25 mL/min or serum creatinine exceeds 
2 mg/dL [16, 17, 20]. 
Repaglinide
The PK properties of repaglinide in patients with CKD 
are similar to those described above for SU: the drug is 
almost entirely metabolised by the liver and only 8–10% 
is excreted unchanged with the urine. Dose adjustment 
is not necessary in patients with CKD, although cau-
tion is advised because the drug may eventually lead 
to profound hypoglycaemia when used in advanced 
stages of CKD (especially with other glucose-lowering 
agents) [14, 16, 27]. 
GLP-1 analogues (GLP-1 receptor agonists)  
GLP1 analogues available in the market differ in their 
PK characteristics. Liraglutide is not excreted by the kid-
neys: dosing does not need any adjustment until GFR 
value falls below 30 mL/min (when GFR is lower than 
30 mL/min/1.73 m2 the drug is not contraindicated, but 
limited experience in this range of GFR is emphasised by 
the manufacturer). The drug should not be prescribed 
in advanced CKD (< 15 mL/min/1.73 m2) and ESRD. In 
the LEADER trial, it was demonstrated that treatment 
with liraglutide decreased the rate of cardiovascular 
and all-cause death and greater benefit was obtained in 
patients with eGFR < 60 mL/min/1.73 m2, as compared 
to those with eGFR above this limit (a small number 
of patients with eGFR < 30 mL/min/1.73 m2 were also 
included in this trial, and the benefits in this group were 
also comparable) [29–32]. 
Exenatide is excreted by the kidneys, but it can still 
be used in quite a wide range of GFR values. If GFR is 
higher than 50 mL/min, the dose does not need adjust-
ment; careful dose titration from 2 × 5 µg/d to 2 × 10 
µg/d is recommended when GRF drops to the range 
of 30–50 mL/min. Regular (short-acting) formulation 
of exenatide should not be used in patients with cre-
atinine clearance of less than 30 mL/min; interestingly, 
the manufacturer does not recommend its use even 
in patients with ClCr of 30–50 mL/min in the case of 
long-acting formulation [33]. 
Dulaglutide (similarly to extended-release exena-
tide) is given once weekly. No significant correlation 
was found between the PK of the drug and creatinine 
clearance; patients with reduced GFR did not experi-
ence more adverse effects of the drug [25]. Nevertheless, 
treatment with dulaglutide is now contraindicated in 
CKD patients with ClCr lower than 30 mL/min, mostly 
due to limited experience in CKD stages 4 and 5 [25]. 
Dose adjustment is not necessary across the whole 
ClCr range exceeding 30 mL/min. Dulaglutide dem-
onstrated its efficacy in reduction of the composite 
cardio-vascular end-point (p = 0.026 vs. placebo) in 
the cardio-vascular outcome trial (CVOT), but did not 
reduce any of the separate contributing events, except 
for non-fatal stroke. Dulaglutide also failed to reduce 
the mortality of patients participating in the REWIND 
trial [34, 35]. In the REWIND trial a very small percent-
age of patients (1%) suffered from advanced CKD (i.e. 
eGFR < 30 mL/min/1.73 m2) at baseline. Dulaglutide 
was nephroprotective, significantly reducing composite 
renal outcome, which was entirely due to reduction of 
new onset of macroalbuminuria [35]. 
DPP4 inhibitors 
Sitagliptin, predominantly (in up to 90%) excreted with 
urine as an active drug, accumulates in CKD. Despite 
precautions suggested by the manufacturer for CKD 
patients, the drug was generally well tolerated and 
effective in improving metabolic control of T2D also 
in this patient group [36]. Vildagliptine is also safe 
and effective in CKD patients, despite the fact that 
the drug is metabolised by the kidneys and excreted 
with urine. In adjusted doses it can still be used even 
in the advanced stages of CKD [37]. The same is true 
for saxagliptin, which is considered a safe and effec-
tive drug across all stages of CKD and even in patients 
treated with dialysis (when the dose needs to be re-
duced to 2.5 mg/d vs. standard 5 mg/d). Vildagliptin 
and saxagliptin bind to plasma proteins in less than 
10%; sitagliptin is protein-bound in 30–40%, whereas 
linagliptin — in more than 80%. Only 1% of linagliptin 
dose is eliminated by the kidneys, and thus linagliptin 
does not need any dose adjustment across all stages of 
CKD [27]. It seems to be the most convenient drug to be 
used in CKD patients at present (unless not contrain-
dicated for other reasons). Unfortunately the drug did 
not reduce the risk of cardiovascular and renal events 
in the high-risk population of patients included in the 
CARMELINA trial (in 75% of patients eGFR was lower 
than 60 mL/min/1.73 m2 and/or proteinuria higher than 
300 mg/g of creatinine; 15.2% of patients suffered from 
advanced CKD with eGFR < 30 mL/min/1.73 m2). This 
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study seems to be the largest trial to date that was 
focused particularly on patients with T2D and CKD. 
It should be mentioned that treatment with linagliptin 
in this high-risk population was not associated with 
an increased risk of hospitalisation due to heart failure 
(which was the case of alogliptin and saxagliptin in pre-
vious trials) [38]. Because heart failure is a very frequent 
co-morbid condition in patients with T2D and CKD, the 
latter finding may be of particular importance when 
choosing glucose-lowering drugs in advanced CKD. 
SGLT-2 inhibitors (SGLT2i)
Sodium — glucose co-transporter type 2 (SGLT-2) inhibi-
tors have recently attract the attention of the nephrologi-
cal community because the glucose-lowering (metabolic) 
effects of these drugs as well as their impact on “hard” 
outcomes are achieved (among others) through the 
“renal” mechanisms of action, resulting in enhanced 
(“therapeutic”) glycosuria and augmented natriuresis.  
In the human physiology SGLT-2 is responsible for 
almost complete (up to 100%) reabsorption of glucose 
in proximal tubules. Hyperglycaemia upregulates the 
SGT2 expression, which enhances reabsorption capacity. 
This mechanism has a negative impact on the metabo-
lism, and blocking activity of SGLT-2 with specific in-
hibitors (resulting in ‘therapeutic glycosuria’) constitutes 
a novel approach to the treatment of T2D (which is en-
tirely independent from glucose synthesis, secretion, or 
sensitivity) [39–42]. Recently published papers pivotally 
demonstrated that SGLT2 inhibitors significantly reduce 
the risk of cardiovascular events, cardiovascular mor-
tality, and all-cause mortality. Depending on the drug 
(empagliflozin, canagliflozin, dapagliflozin), these ef-
fects differ slightly, but in principle the cardio-protective 
mechanisms can be attributed to all of them (class effect). 
Similarly, all these drugs contribute also to nephropro-
tection in T2D [43]. The positive impact of the mentioned 
drug class on cardio-vascular endpoints is not only due 
to better metabolic control of T2D (in fact, their impact 
on glycaemia and HbA1c is relatively modest). These 
drugs also decrease body weight, reduce blood pressure, 
improve heart function with decreased oxygen demand 
for myocardium, reduce oxidative stress, decrease sym-
pathetic nervous system activation, reduce serum uric 
acid level, and possess properties of weak diuretics.  In 
the kidney they reduce oxygen consumption by the 
proximal tubules because less energy is needed when 
sodium and glucose reabsorption are substantially 
limited. An additional mechanism that may impact on 
blood pressure and natriuresis is the blockade of sodium 
— proton exchanger type 3 (NHE3). SGLT2i also acti-
vates tubulo-glomerular feedback: the increased sodium 
load in the region of macula densa triggers constriction 
of the afferent arteriole, thus reducing intraglomerular 
pressure and hyperfiltration. This mechanism, although 
based on a different principle, largely resembles the 
effect of ACEI or ARBs, and — as in the case of these 
drugs — may be associated with transient (“acute”) 
but reversible reduction in GFR [39]. At present, the 
summaries of product characteristics of all mentioned 
SGLT2 inhibitors state that they should not be used in 
patients with GFR of less than 60 mL/min/1.73 m2. It has 
been assumed that the significantly reduced number of 
intact proximal tubules and nephrons (i.e. the target for 
SGLT2i) in this stage of CKD precludes the effectiveness 
of these drugs. However, an increasing body of evidence 
suggests that — although less efficient in metabolic 
control of diabetes in more advanced CKD — these 
drugs may still reduce body weight and blood pressure. 
Dapagliflozin was effective in reducing HbA1c, fasting 
blood glucose, body weight, and systolic blood pressure 
also in patients with eGFR ranging between 45 and 
59 mL/min/1.73 m2 (CKD stage 3a; DERIVE study) [44, 
45]. It is worth emphasising that pivotal outcome trials, 
namely EMPA-REG (with empagliflozin) and CANVAS 
(with canagliflozin), enrolled only a small proportion of 
patients with eGFR between 30 and 60 mL/min/1.73 m2 
[46–48]. In the EMPA-REG trial cardiovascular outcomes 
were independent of CKD stage (eGFR value), whereas 
in the CANVAS trial the most significant risk reduction 
of cardio-vascular endpoints was observed in patients 
with eGFR between 30 and 60 mL/min/1.73 m2. Several 
ongoing trials are testing the hypothesis that SGLT21 
and GLP1R agonists are beneficial also in patients with 
significantly reduced eGFR. Recently, the CREDENCE 
trial repeatedly proved the renoprotective efficacy of 
the SGLT2 inhibitor canagliflozin in patients with eGFR 
reduced to less than 60 mL/min/1.73 m2 at baseline. The 
drug decreased the risk of primary outcome comprising 
end-stage renal disease, doubling of serum creatinine 
from baseline, or death from renal or cardiovascular 
causes, with highly significant difference vs. placebo 
(p = 0.00001; the effect was achieved due to reduction in 
doubling of serum creatinine, onset of ESRD, and cardio-
vascular death) [49]. Cardiovascular benefit achieved in 
this trial was — as in the case of cardio-vascular outcome 
trials performed with other drugs — predominantly 
demonstrated in patients with the lowest baseline GFR 
(i.e.< 45 mL/min/1.73 m2) [50].  
The cardio-vascular and renal benefits associated 
with the treatment of SGLT2i and GLP-1R agonists led 
several groups of experts (such as the American Dia-
betes Association [ADA] and the European Association 
for the Studies in Diabetes [EASD]) to publish updated 
algorithms of treatment in high-risk patients with T2D. 
The most recent guidelines published by the ADA and 
EASD suggests the use of SGLT1i and/or GLP1R agonist 
with proven cardio-vascular efficacy in patients with 
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atherosclerotic cardiovascular disease, (ACVD), heart 
failure (HF), or CKD, when metabolic control of T2D 
cannot be achieved with metformin. In terms of reduc-
tion of ACVD in CKD patients with T2D, both drugs are 
considered equally efficient; however, SGLT2i should 
be preferred when HF predominates, whereas GLP1R 
agonist seems to be a better choice in patients with 
more significantly reduced GFR [51]. The ADA/EASD 
guidelines were recently upheld and supported by the 
European Society of Cardiology guidelines on cardio-
vascular disease in diabetes and prediabetes (published 
with collaboration of the EASD). This document made 
a step forward and challenged the “dogma” of modern 
diabetology; namely, it suggested that patients with 
T2D and very high or high cardiovascular risk, who 
are naïve to treatment, should not start treatment with 
metformin as the first drug. Metformin should remain 
an option for patients with low or moderate cardiovas-
cular risk. The experts suggested starting therapy in 
high- and very high-risk patients from SGLT2 inhibi-
tor or GLP1R agonist, listing all available drugs with 
completed CVOTs from both groups. However, they 
specifically pointed out liraglutide and empagliflozin as 
drugs that may reduce not only the risk of a CV event, 
by also the risk of premature death [52]. These guide-
lines seem to be relevant for all patients with T2D and 
CKD of all stages because in most of them the CV risk is 
considered as high or very high. Currently, liraglutide 
seems to be best option for patients with advanced CKD 
(eGFR between 15 and 45 mL/min/1.73 m2).
In Table 3 and 4 we have summarised the available 
data for oral glucose lowering agents and GLP-1R 
Table 3. The use of oral glucose lowering agents and GLP-1R agonists in patients with type 2 diabetes (T2D) and chronic 
kidney disease (CKD)
Groups of drugs/ 
/drugs Limitations for use in patients with CKD (as stated in SPC)
Method of kidney 
function assessment 
(stated in the SPC)
Metformin Contraindicated	if	CrCl1	less	than	60	mL/min Cockcroft-Gault	formula
Pioglitazone	
No	need	for	dose	adjustment	unless	CrCl	>	4	mL/min	
Should	not	be	used	in	patients	on	dialysis
Not	stated2
Repaglinide
CKD	does	not	influence	drug	elimination
No	special	guidelines	in	CKD	patients
AUC	of	the	drug	in	different	CrCl	ranges	described	in	SPC
Not	stated2
Acarbose	 Contraindicated	in	severe	kidney	failure	(CrCl	<	25	mL/min) Not	stated2
Sulphonylurea 
Glipizide CKD/kidney	failure	not	listed	as	contraindications Not	stated2
Glimepiride Contraindicated	in	the	severe	kidney	failure	(“severe	kidney	failure”	not	defined) Not	stated
Gliclazide Contraindicated	in	the	severe	kidney	failure	(“severe	kidney	failure”	not	defined) Not	stated
Gliquidone
CKD/kidney	failure	not	listed	as	contraindications	CKD
In	severe	kidney	failure	(not	defined)	manufacturer	recommends	careful	medical	supervision		
Not	stated
GLP1R agonists 
Exenatide
Dose	adjustment	not	needed	in	the	CrCl	range	between	50	and	80	mL/min
Conservative	dose	escalation	from	5	to	10	μg	recommended	in	patients		
with	CrCl	30–50	mL/min
Not	recommended	for	use	in	patients	with	CrCl	<	30	mL/min	and	ESRD
Not	stated2
Liraglutide
No	dose	adjustment	is	required	for	patients	with	mild,	moderate,	or	severe	renal	impairment.	
There	is	no	therapeutic	experience	in	patients	with	end-stage	renal	disease,	and	the	drug	is	
therefore	not	recommended	for	use	in	these	patients
Not	stated
Dulaglutide
No	dosage	adjustment	is	required	in	patients	with	mild,	moderate,	or	severe	renal	impairment	
(eGFR	<	90	to	≥15	mL/min/1.73	m2)
There	is	very	limited	experience	in	patients	with	end-stage	renal	disease		
(eGFR	<	15	mL/min/1.73	m2);	therefore,	the	drug	cannot	be	recommended	in	this	population
CKD-EPI
DPP4 inhibitors
Linagliptin For	patients	with	renal	impairment,	no	dose	adjustment	for	linagliptin	is	required
24-hour	urine	collection-
based	CrCl	or	Cockcroft-	
-Gault	formula	mentioned	
as	used	in	clinical	trials	
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Table 3. The use of oral glucose lowering agents and GLP-1R agonists in patients with type 2 diabetes (T2D) and chronic 
kidney disease (CKD)
Groups of drugs/ 
/drugs Limitations for use in patients with CKD (as stated in SPC)
Method of kidney 
function assessment 
(stated in the SPC)
Saxagliptin
No	dose	adjustment	is	recommended	for	patients	with	mild	renal	impairment	or	in	patients	
with	moderate	renal	impairment	that	have	GFR	≥	45	mL/min/1.73	m2
The	dose	should	be	reduced	to	2.5	mg	once	daily	in	patients	with	moderate	renal	impairment	
and	GFR	<	45	mL/min/1.73	m2	and	in	patients	with	severe	renal	impairment
Saxagliptin	is	not	recommended	for	patients	with	ESRD	requiring	haemodialysis
Not	stated
Sitagliptin
For	patients	with	mild	renal	impairment	(GFR	<	60	to	<	90	mL/min/1.73	m2),	no	dose	
adjustment	is	required
For	patients	with	moderate	renal	impairment	(GFR<	45	to	<	60	mL/min//1.73	m2),	no	dosage	
adjustment	is	required
For	patients	with	moderate	renal	impairment	(GFR	>	30	to	<	45	mL/min/1.73	m2),	the	dose	is	
50	mg	once	daily
For	patients	with	severe	renal	impairment	(GFR	≥	15	to	<	30	mL/min/1.73	m2)	or	with	ESRD	
(GFR	<	15	mL/min/1.73	m2),	including	those	requiring	haemodialysis	or	peritoneal	dialysis,	the	
dose	is	25	mg	once	daily
Treatment	may	be	administered	without	regard	to	the	timing	of	dialysis
Not	stated
Vildagliptin
No	dose	adjustment	is	required	in	patients	with	mild	renal	impairment	(CrCl		
≥	50	mL/min)
Recommended	daily	dose	50	mg	BID
In	patients	with	moderate	or	severe	renal	impairment	or	with	ESRD,	the	recommended	dose	is	
50	mg	once	daily
Due	to	limited	experience	it	should	be	used	with	caution	in	patients	on	haemodialysis	
Not	stated
SGLT2 inhibitors
Dapagliflozin Should	not	be	initiated	in	patients	with	GFR<	60	mL/min/1.73	m
2	and	should	be	discontinued	
in	patients	with	GFR	persistently	<	45	mL/min/1.73	m2 Not	stated
Empagliflozin
No	dose	adjustment	is	required	for	patients	with	an	eGFR	≥	60	mL/min/1.73	m2	
or	CrCl	≥	60	mL/min2	
Empagliflozin	should	not	be	initiated	in	patients	with	an	eGFR	<	60	mL/min/1.73	m2	
or	CrCl	<	60	mL/min
In	patients	tolerating	empagliflozin,	whose	eGFR	falls	persistently	below	60	mL/min/1.73	m2	
or	CrCl	below	60	mL/min,	the	dose	of	empagliflozin	should	be	adjusted	to	or	maintained		
at	10	mg	once	daily
Empagliflozin	should	be	discontinued	when	eGFR	is	persistently	below	45	mL/min/1.73	m2	
or	CrCl	persistently	below	45	mL/min	(see	sections	4.4,	4.8,	5.1,	and	5.2).
Empagliflozin	should	not	be	used	in	patients	with	ESRD	or	in	patients	on	dialysis	because	it	is	
not	expected	to	be	effective	in	these	patients
Not	stated	for	CrCl	
measurement	or	eGFR	
calculation;	MDRD	
formula	mentioned	in	
SPC	as	used	in	one	of	
the	clinical	trials		
Canagliflozin
For	patients	with	an	eGFR	60	mL/min/1.73	m2	to	<	90	mL/min/1.73	m2	or	CrCl	60	mL/min	
to	<	90	mL/min,	no	dose	adjustment	is	needed2
Canagliflozin	should	not	be	initiated	in	patients	with	an	eGFR	<	60	mL/min/1.73	m2	
or	CrCl	<	60	mL/min
In	patients	tolerating	canagliflozin,	whose	eGFR	falls	persistently	below	60	mL/min/1.73	m2	
or	CrCl	60	mL/min,	the	dose	of	canagliflozin	should	be	adjusted	to	or	maintained	at	100	mg	
once	daily
Canagliflozin	should	be	discontinued	when	eGFR	is	persistently	below	45	mL/min/1.73	m2	
or	CrCl	persistently	below	45	mL/min
Not	stated	for	CrCl	
measurement	or	eGFR	
calculation	
bid	—	twice	a	day;	CKD-EPI	—	Chronic	Kidney	Disease-Epidemiology	Collaboration;	CrCl	—	creatinine	clearance;	ESRD	—	end-stage	renal	disease;	GFR	—	glomerular	
filtration	rate;	MDRD	—	Modification	of	Diet	in	Renal	Disease;	SPC	—	summary	of	product	characteristics;
1the	terms	“creatinine	clearance”	(ClCr),	“estimated	glomerular	filtration	rate”	(eGFR),	or	both	were	used	in	Table	3	according	to	the	terms	used	in	SPCs	of	the	respective	
products;	2presumably	the	Cockcroft-Gault	formula;	2we	believe	that	the	statement	of	“eGFR	or	CrCl”	is	highly	imprecise	because	both	values	may	significantly	differ	in	
the	same	person	using	the	same	serum	creatinine	value	for	calculations	
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agonists used in patients with T2D and CKD that are 
available in Poland, with particular focus on their dos-
age adjustment to the GFR range. 
Insulin
As mentioned above, advanced CKD impairs insulin 
secretion and enhances insulin resistance; on the 
other hand, reduced contribution of the kidneys to 
insulin catabolism and clearance may paradoxically 
increase the effect of exogenous insulin (up to 30% 
of insulin inactivation or elimination is performed in 
the kidneys). It is believed (but this opinion is entirely 
expert based, not supported by clinical trials) that 
the demand for exogenous insulin is decreased on 
average by 20% to 30% when GFR is reduced to 10 to 
50 mL/min, as compared to GFR > 50 mL/min. In CKD 
stage 5 (ESRD) this demand may be even halved com-
pared to normal kidney function. Particular dialysis 
techniques used for the treatment of ESRD generate 
special challenges. In patients treated with peritoneal 
dialysis additional intraperitoneal glucose load must 
be handled because a significant amount of glucose 
is absorbed into the bloodstream. Additional doses 
of insulin need to be prescribed to manage this extra 
glucose load. A very unique challenge of haemodialy-
sis (HD) when treating diabetes is the “intermittent” 
nature of therapy — every second day (i.e. day with 
a dialysis session) is substantially different from the 
days off dialysis in terms of the metabolic situation: 
patients have their routine daily schedule (including 
physical activity, meals, etc.) disturbed by dialysis 
treatment itself, travelling to and from the dialysis 
unit (which may together last up to 8–10 hours every 
second day), substantial changes in volume status, 
acid-base balance parameters, electrolytes, etc. There 
is an ongoing discussion in the literature about which 
type of insulin would be more suitable for patients 
treated with intermittent HD. No clear recommen-
dations could be established until now — some 
authors prefer short-acting insulins, whereas others 
suggest long-acting formulas. Sometimes different 
dosing schedules are proposed for days on dialysis 
and off dialysis, although such an approach remains 
largely impractical and inconvenient. It seems that 
the PK characteristics of insulin analogues are less 
disturbed compared to human insulin formulas in HD 
patients. Specific guidelines for insulin therapy in the 
maintenance of dialysis patients have not been devel-
oped; generally accepted approaches are also adopted 
for this group of patients (with special considerations 
applicable for specific types of dialysis). Less stringent 
goals of metabolic control should certainly be applied 
in this patient group [5, 53, 54]. 
Acknowledgments 
This position statement was kindly reviewed by Pro-
fessor Krzysztof Strojek, National Consultant in Dia-
betes. The authors would like to express their deepest 
thanks for his effort to improve this manuscript; all his 
valuable comments and corrections were implemented 
into the final version of the manuscript.  
References
1. Jaacks LM, Siegel KR, Gujral UP, et al. Type 2 diabetes: A 21st century 
epidemic. Best Pract Res Clin Endocrinol Metab. 2016; 30(3): 331–343, 
doi: 10.1016/j.beem.2016.05.003, indexed in Pubmed: 27432069.
2. Pyram R, Kansara A, Banerji MA, et al. Chronic kidney disease and dia-
betes. Maturitas. 2012; 71(2): 94–103, doi: 10.1016/j.maturitas.2011.11.009, 
indexed in Pubmed: 22137331.
3. Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with 
T2DM: prevalence, temporal trends, and treatment patterns-NHANES 
2007-2012. BMJ Open Diabetes Res Care. 2016; 4(1): e000154, 
doi: 10.1136/bmjdrc-2015-000154, indexed in Pubmed: 27110365.
4. Pugliese G, Solini A, Bonora E, et al. RIACE Study Group. Chronic kidney 
disease in type 2 diabetes: lessons from the Renal Insufficiency And 
Cardiovascular Events (RIACE) Italian Multicentre Study. Nutr Metab 
Cardiovasc Dis. 2014; 24(8): 815–822, doi: 10.1016/j.numecd.2014.02.013, 
indexed in Pubmed: 24780515.
5. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 
2008; 10: 811–823, doi:  10.1111/j.1463-1326.2007.00802.x, indexed in 
Pubmed: 18248491.
6. Xu H, Carrero JJ. Insulin resistance in chronic kidney disease. Nephrol-
ogy (Carlton). 2017; 22(Suppl 4): 31–34, doi: 10.1111/nep.13147, indexed 
in Pubmed: 29155496.
7. Leyking S, Fliser D. Insulin resistance in CKD. Clin J Am Soc 
Nephrol. 2014; 9(4): 638–640, doi:  10.2215/CJN.01290214, indexed in 
Pubmed: 24677558.
8. Sharif A, Hecking M, de Vries APJ, et al. Proceedings from an inter-
national consensus meeting on posttransplantation diabetes mellitus: 
recommendations and future directions. Am J Transplant. 2014; 14(9): 
1992–2000, doi: 10.1111/ajt.12850, indexed in Pubmed: 25307034.
9. Fathallah N, Slim R, Larif S, et al. Drug-Induced Hyperglycaemia and Di-
abetes. Drug Saf. 2015; 38(12): 1153–1168, doi: 10.1007/s40264-015-0339-z, 
indexed in Pubmed: 26370106.
10. Kovesdy CP, Sharma K, Kalantar-Zadeh K. Glycemic control in diabetic 
CKD patients: where do we stand? Am J Kidney Dis. 2008; 52(4): 766–777, 
doi: 10.1053/j.ajkd.2008.04.011, indexed in Pubmed: 18572289.
11. Guideline development group. Clinical Practice Guideline on manage-
ment of patients with diabetes and chronic kidney disease stage 3b or 
higher (eGFR <45 mL/min). Nephrol Dial Transplant. 2015; 30 Suppl 2: 
ii1–142, doi: 10.1093/ndt/gfv100, indexed in Pubmed: 25940656.
12. Roche-Recinos A, Charlap E, Markell M. Management of glycemia in 
diabetic patients with stage IV and V chronic kidney disease. Curr 
Diab Rep. 2015; 15(5): 25, doi:  10.1007/s11892-015-0600-y, indexed in 
Pubmed: 25772643.
13. American Diabetes Association . Updates to theStandards of Medi-
cal Care in Diabetes — 2018. Diabetes Care. 2018; 41(9): 2045–2047, 
doi: 10.2337/dc18-su09, indexed in Pubmed: 30135199 .
14. Gianchandani RY, Neupane S, Heung M. Hypoglycemia in Hospital-
ized Hemodialysis Patients With Diabetes: An Observational Study. J 
Diabetes Sci Technol. 2018; 12(1): 33–38, doi: 10.1177/1932296817747620, 
indexed in Pubmed: 29291650.
15. Schernthaner G, Ritz E, Schernthaner GH. Strict glycaemic control in 
diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol Dial 
Transplant. 2010; 25(7): 2044–2047, doi: 10.1093/ndt/gfq199, indexed in 
Pubmed: 20388630.
16. Arnouts P, Bolignano D, Nistor I, et al. Glucose-lowering drugs in 
patients with chronic kidney disease: a narrative review on pharma-
cokinetic properties. Nephrol Dial Transplant. 2014; 29(7): 1284–1300, 
doi: 10.1093/ndt/gft462, indexed in Pubmed: 24322578.
17. Di Lullo L, Mangano M, Ronco C, et al. The treatment of type 2 
diabetes mellitus in patients with chronic kidney disease: What to 
expect from new oral hypoglycemic agents. Diabetes Metab Syndr. 
2017; 11 Suppl 1: S295–S305, doi:  10.1016/j.dsx.2017.03.005, indexed 
in Pubmed: 28292575.
18. Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 
2 diabetes and kidney disease: a systematic review. JAMA. 2014; 312(24): 
2668–2675, doi: 10.1001/jama.2014.15298, indexed in Pubmed: 25536258.
19. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting 
of mild-to-moderate renal insufficiency. Diabetes Care. 2011; 34(6): 
1431–1437, doi: 10.2337/dc10-2361, indexed in Pubmed: 21617112.
14
G
u
id
e
l
in
e
s
Diagnosis and treatment of type 2 diabetes mellitus Tomasz Stompór et al.
20. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report 
from an ADA Consensus Conference. Diabetes Care. 2014; 37(10): 
2864–2883, doi: 10.2337/dc14-1296, indexed in Pubmed: 25249672.
21. Penfornis A, Blicklé JF, Fiquet B, et al. How are patients with type 2 
diabetes and renal disease monitored and managed? Insights from the 
observational OREDIA study. Vasc Health Risk Manag. 2014; 10: 341–352, 
doi: 10.2147/VHRM.S60312, indexed in Pubmed: 24966684.
22. Lalau JD, Kajbaf F, Bennis Y, et al. Metformin Treatment in Patients 
With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4. 
Diabetes Care. 2018; 41(3): 547–553, doi: 10.2337/dc17-2231, indexed in 
Pubmed: 29305402.
23. Kuo CC, Yeh HC, Chen B, et al. Prevalence of Metformin Use and the 
Associated Risk of Metabolic Acidosis in US Diabetic Adults With CKD: 
A National Cross-Sectional Study. Medicine (Baltimore). 2015; 94(51): 
e2175, doi: 10.1097/MD.0000000000002175, indexed in Pubmed: 26705203.
24. Schneider CA, Ferrannini E, Defronzo R, et al. Effect of pioglitazone on 
cardiovascular outcome in diabetes and chronic kidney disease. J Am 
Soc Nephrol. 2008; 19(1): 182–187, doi: 10.1681/ASN.2007060678, indexed 
in Pubmed: 18057215.
25. Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in 
the presence of renal impairment: what we should know about newer 
therapies. Clin Pharmacol. 2016; 8: 61–81, doi:  10.2147/CPAA.S82008, 
indexed in Pubmed: 27382338.
26. Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical Review of An-
tidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. 
Front Endocrinol (Lausanne). 2017; 8: 6, doi: 10.3389/fendo.2017.00006, 
indexed in Pubmed: 28167928.
27. Roussel R, Lorraine J, Rodriguez A, et al. Overview of Data Concern-
ing the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes 
Mellitus and Chronic Kidney Disease. Adv Ther. 2015; 32(11): 1029–1064, 
doi: 10.1007/s12325-015-0261-x, indexed in Pubmed: 26581749.
28. Abe M, Okada K, Abe M, et al. Antidiabetic agents in patients with 
chronic kidney disease and end-stage renal disease on dialysis: metabo-
lism and clinical practice. Curr Drug Metab. 2011; 12(1): 57–69, doi: 10.2
174/138920011794520053, indexed in Pubmed: 21303332.
29. Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies 
in patients with chronic kidney disease and type 2 diabetes. Clin Phar-
macokinet. 2015; 54(1): 1–21, doi: 10.1007/s40262-014-0198-2, indexed in 
Pubmed: 25331711.
30. Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: 
from physiology to pharmacology and outcomes in diabetes. Nat 
Rev Nephrol. 2017; 13: 605, doi: 10.1038/nrneph.2017.123, indexed in 
Pubmed: 28869249.
31. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering 
Committee, LEADER Trial Investigators. Liraglutide and Cardiovascu-
lar Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4): 311–322, 
doi: 10.1056/NEJMoa1603827, indexed in Pubmed: 27295427.
32. Mann JFE, Ørsted DD, Buse JB, et al. LEADER Steering Committee and 
Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N 
Engl J Med. 2017; 377(9): 839–848, doi: 10.1056/NEJMoa1616011, indexed 
in Pubmed: 28854085.
33. Mentz RJ, Bethel MA, Merrill P, et al. EXSCEL Study Group, EXSCEL 
Study Group. Effects of Once-Weekly Exenatide on Cardiovascular 
Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(13): 1228–1239, 
doi: 10.1056/NEJMoa1612917, indexed in Pubmed: 28910237.
34. Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investiga-
tors. Dulaglutide and cardiovascular outcomes in type 2 diabetes (RE-
WIND): a double-blind, randomised placebo-controlled trial. Lancet. 
2019; 394(10193): 121–130, doi: 10.1016/S0140-6736(19)31149-3, indexed 
in Pubmed: 31189511.
35. Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investiga-
tors. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory 
analysis of the REWIND randomised, placebo-controlled trial. Lancet. 
2019; 394(10193): 131–138, doi: 10.1016/S0140-6736(19)31150-X, indexed 
in Pubmed: 31189509.
36. Engel SS, Suryawanshi S, Stevens SR, et al. TECOS Study Group. Safety 
of sitagliptin in patients with type 2 diabetes and chronic kidney disease: 
outcomes from TECOS. Diabetes Obes Metab. 2017; 19(11): 1587–1593, 
doi: 10.1111/dom.12983, indexed in Pubmed: 28432745.
37. Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate 
or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. 
Diabetes Metab Syndr Obes. 2013; 6: 161–170, doi: 10.2147/DMSO.S28951, 
indexed in Pubmed: 23650450.
38. Rosenstock J, Perkovic V, Johansen OE, et al. CARMELINA Investiga-
tors. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in 
Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: 
The CARMELINA Randomized Clinical Trial. JAMA. 2019; 321(1): 69–79, 
doi: 10.1001/jama.2018.18269, indexed in Pubmed: 30418475.
39. Wanner C. EMPA-REG OUTCOME: The Nephrologist’s Point of View. 
Am J Med. 2017; 130(6S): S63–S72, doi: 10.1016/j.amjmed.2017.04.007, 
indexed in Pubmed: 28526179.
40. Heerspink HJL, Perkins BA, Fitchett DH, et al. Sodium Glucose Co-
transporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Car-
diovascular and Kidney Effects, Potential Mechanisms, and Clinical 
Applications. Circulation. 2016; 134(10): 752–772, doi: 10.1161/CIRCU-
LATIONAHA.116.021887, indexed in Pubmed: 27470878.
41. Perrone-Filardi P, Avogaro A, Bonora E, et al. Mechanisms linking 
empagliflozin to cardiovascular and renal protection. Int J Car-
diol. 2017; 241: 450–456, doi: 10.1016/j.ijcard.2017.03.089, indexed in 
Pubmed: 28395981.
42. Schernthaner G, Mogensen CE, Schernthaner GH. The effects of GLP-1 
analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. 
Diab Vasc Dis Res. 2014; 11(5): 306–323, doi: 10.1177/1479164114542802, 
indexed in Pubmed: 25116004.
43. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascu-
lar outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347–357, 
doi: 10.1056/NEJMoa1812389, indexed in Pubmed: 30415602.
44. Fioretto P, Del Prato S, Buse JB, et al. DERIVE Study Investigators. Efficacy 
and safety of dapagliflozin in patients with type 2 diabetes and moderate 
renal impairment (chronic kidney disease stage 3A): The DERIVE Study. 
Diabetes Obes Metab. 2018; 20(11): 2532–2540, doi: 10.1111/dom.13413, 
indexed in Pubmed: 29888547.
45. Dekkers CCJ, Wheeler DC, Sjöström CD, et al. Effects of the sodi-
um-glucose co-transporter 2 inhibitor dapagliflozin in patients with 
type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrol Dial 
Transplant. 2018; 33(11): 2005–2011, doi: 10.1093/ndt/gfx350, indexed in 
Pubmed: 29370424.
46. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular 
and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644–657, 
doi: 10.1056/NEJMoa1611925, indexed in Pubmed: 28605608.
47. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular 
outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 
2117–2128, doi: 10.1056/NEJMoa1504720, indexed in Pubmed: 26378978 .
48. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression 
of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323–334, 
doi: 10.1056/NEJMoa1515920, indexed in Pubmed: 27299675.
49. Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investiga-
tors. Canagliflozin and Renal Outcomes in Type 2 Diabetes and 
Nephropathy. N Engl J Med. 2019; 380(24): 2295–2306, doi: 10.1056/NEJ-
Moa1811744, indexed in Pubmed: 30990260.
50. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and Cardio-
vascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic 
Kidney Disease in Primary and Secondary Cardiovascular Prevention 
Groups. Circulation. 2019; 140(9): 739–750, doi:  10.1161/CIRCULA-
TIONAHA.119.042007, indexed in Pubmed: 31291786.
51. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hypergly-
caemia in type 2 diabetes, 2018. A consensus report by the American 
Diabetes Association (ADA) and the European Association for the 
Study of Diabetes (EASD). Diabetologia. 2018; 61(12): 2461–2498, 
doi: 10.1007/s00125-018-4729-5, indexed in Pubmed: 30288571.
52. Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document 
Group . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovas-
cular diseases developed in collaboration with the EASD. Eur Heart J. 
2019 [Epub ahead of print], doi: 10.1093/eurheartj/ehz486, indexed in 
Pubmed: 31497854.
53. Rajput R, Sinha B, Majumdar S, et al. Consensus statement on insulin 
therapy in chronic kidney disease. Diabetes Res Clin Pract. 2017; 127: 
10–20, doi: 10.1016/j.diabres.2017.02.032, indexed in Pubmed: 28315574.
54. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications 
in patients with diabetes mellitus and advanced kidney disease. Semin 
Dial. 2004; 17(5): 365–370, doi: 10.1111/j.0894-0959.2004.17346.x, indexed 
in Pubmed: 15461745.
